These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11098342)

  • 1. Seizure possibly associated with fluvoxamine.
    Kim KY; Craig JM; Hawley JM
    Ann Pharmacother; 2000 Nov; 34(11):1276-8. PubMed ID: 11098342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Dose Fluvoxamine Augmentation to Clozapine in Treatment-Resistant Psychosis.
    Leising J; Barr AM; Procyshyn RM; Ainsworth NJ; White RF; Honer W; Vila-Rodriguez F
    J Clin Psychopharmacol; 2021 Mar-Apr 01; 41(2):186-190. PubMed ID: 33587389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial.
    Shalbafan M; Malekpour F; Tadayon Najafabadi B; Ghamari K; Dastgheib SA; Mowla A; Shirazi E; Eftekhar Ardebili M; Ghazizadeh-Hashemi M; Akhondzadeh S
    J Psychopharmacol; 2019 Nov; 33(11):1407-1414. PubMed ID: 31575326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin syndrome and fluvoxamine: a case study.
    Bastani JB; Troester MM; Bastani AJ
    Nebr Med J; 1996 Apr; 81(4):107-9. PubMed ID: 8628448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A seizure, and electroencephalographic signs of a lowered seizure threshold, associated with fluvoxamine treatment of obsessive-compulsive disorder.
    Trabert W; Hohagen F; Winkelmann G; Berger M
    Pharmacopsychiatry; 1995 May; 28(3):95-7. PubMed ID: 7568372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison.
    Koran LM; McElroy SL; Davidson JR; Rasmussen SA; Hollander E; Jenike MA
    J Clin Psychopharmacol; 1996 Apr; 16(2):121-9. PubMed ID: 8690827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A display of hypomania in a depressed male in response to fluvoxamine.
    Horiguchi T; Sai S
    World J Biol Psychiatry; 2001 Oct; 2(4):201-4. PubMed ID: 12587152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased libido in a woman treated with fluvoxamine: a case report.
    Hori H; Yoshimura R; Nakamura J
    Acta Psychiatr Scand; 2001 Apr; 103(4):312-4. PubMed ID: 11328247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression.
    Apter A; Ratzoni G; King RA; Weizman A; Iancu I; Binder M; Riddle MA
    J Am Acad Child Adolesc Psychiatry; 1994; 33(3):342-8. PubMed ID: 8169178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restlessness related to SSRI withdrawal.
    Hirose S
    Psychiatry Clin Neurosci; 2001 Feb; 55(1):79-80. PubMed ID: 11235863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of sexual dysfunction in healthy volunteers on fluvoxamine therapy.
    Nafziger AN; Bertino JS; Goss-Bley AI; Kashuba AD
    J Clin Psychiatry; 1999 Mar; 60(3):187-90. PubMed ID: 10192595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Violent acts associated with fluvoxamine treatment.
    Okada F; Okajima K
    J Psychiatry Neurosci; 2001 Sep; 26(4):339-40. PubMed ID: 11590975
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study.
    Mundo E; Bareggi SR; Pirola R; Bellodi L; Smeraldi E
    J Clin Psychopharmacol; 1997 Feb; 17(1):4-10. PubMed ID: 9004050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disinhibition as a side effect of treatment with fluvoxamine in pediatric patients with obsessive-compulsive disorder.
    Harris E; Eng HY; Kowatch R; Delgado SV; Saldaña SN
    J Child Adolesc Psychopharmacol; 2010 Aug; 20(4):347-53. PubMed ID: 20807074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
    Hollander E; Koran LM; Goodman WK; Greist JH; Ninan PT; Yang H; Li D; Barbato LM
    J Clin Psychiatry; 2003 Jun; 64(6):640-7. PubMed ID: 12823077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Citalopram and fluvoxamine in Tourette's disorder.
    Bajo S; Battaglia M; Pegna C; Bellodi L
    J Am Acad Child Adolesc Psychiatry; 1999 Mar; 38(3):230-1. PubMed ID: 10087681
    [No Abstract]   [Full Text] [Related]  

  • 17. Complex movement disorder associated with fluvoxamine.
    Bronner IM; Vanneste JA
    Mov Disord; 1998 Sep; 13(5):848-50. PubMed ID: 9756160
    [No Abstract]   [Full Text] [Related]  

  • 18. Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive-compulsive disorder: A double-blind randomized trial with placebo control.
    Naderi S; Faghih H; Aqamolaei A; Mortazavi SH; Mortezaei A; Sahebolzamani E; Rezaei F; Akhondzadeh S
    Psychiatry Clin Neurosci; 2019 Apr; 73(4):169-174. PubMed ID: 30488617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse effects of long-term administration of fluvoxamine on haematology, blood biochemistry and fertility in male albino rats: a possible effect of cessation.
    Galal AA; Alam RT; Abd El-Aziz RM
    Andrologia; 2016 Nov; 48(9):914-922. PubMed ID: 26771175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents.
    Reinblatt SP; DosReis S; Walkup JT; Riddle MA
    J Child Adolesc Psychopharmacol; 2009 Apr; 19(2):119-26. PubMed ID: 19364290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.